Acalabrutinib Alternatives Compared
| Acalabrutinib | Imbruvica (ibrutinib) | Brukinsa (zanubrutinib) |
|
|---|
| Acalabrutinib | Imbruvica (ibrutinib) | Brukinsa (zanubrutinib) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma. Acalabrutinib may also be used for purposes not listed in this medication guide. |
Prescription only
Imbruvica is used to treat certain types of cancers in adults or to treat chronic Graft Versus Host disease in adults and children older than 1 year. It an oral tablet that may be taken once daily... View more |
Prescription only
Prescribed for Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma. Brukinsa may also be used for purposes not listed in... View more |
||||||||||||||||
| More about Acalabrutinib | More about Imbruvica (ibrutinib) | More about Brukinsa (zanubrutinib) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Acalabrutinib has an average rating of 8.7 out of 10 from a total of 40 ratings on Drugs.com. 88% of reviewers reported a positive effect, while 5% reported a negative effect. |
Imbruvica has an average rating of 6.6 out of 10 from a total of 69 ratings on Drugs.com. 59% of reviewers reported a positive effect, while 30% reported a negative effect. |
Brukinsa has an average rating of 8.6 out of 10 from a total of 45 ratings on Drugs.com. 78% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Acalabrutinib side effects |
View all Imbruvica side effects |
View all Brukinsa side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Imbruvica prices |
View all Brukinsa prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Calquence |
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
6.9 hours |
6 hours |
4 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 511 drugs are known to interact with Acalabrutinib:
|
A total of 510 drugs are known to interact with Imbruvica:
|
A total of 531 drugs are known to interact with Brukinsa:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
|
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
October 31, 2017 |
November 13, 2013 |
November 14, 2019 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.